Latest Anticonvulsants Stories
-- Primary efficacy and safety data from the largest Phase 3 brivaracetam study involving 768 patients presented at the 68th Annual Meeting of the American Epilepsy Society BRUSSELS, Dec.
-- Results of Investigational Studies of Perampanel and Rufinamide Accepted as Late-Breaking Posters -- WOODCLIFF LAKE, N.J., Dec. 5, 2014 /PRNewswire/ -- Eisai Inc.
- 24 UCB-sponsored presentations including new data on VIMPAT® (lacosamide) BRUSSELS, Dec.
Global Epilepsy Market 2014-2018 profiles key players like GlaxoSmithKline plc, Pfizer Inc. and UCB SA.
Findings Presented at 43rd Annual Meeting of the Child Neurology Society MAPLE GROVE, Minn., Oct.
WOODCLIFF LAKE, N.J., Oct. 20, 2014 /PRNewswire/ -- Eisai Inc. announced today that the U.S.
RnRMarketResearch.com adds “Partial Seizure – Pipeline Review, H2 2014” to its store.
MarketOptimizer.org adds “PharmaPoint Epilepsy – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update” to its store.
NEWARK, Calif., Sept. 5, 2014 /PRNewswire/ -- Depomed, Inc.
- VIMPAT® (lacosamide) C-V approved in the U.S. as monotherapy in the treatment of partial-onset seizures in adults with epilepsy(1) BRUSSELS, Sept.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.